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Within a prospective protocol, the incidence and impact of achievement of molecular remission (mCR) and
high-risk cytogenetics was investigated in 73 patients with multiple myeloma (MM) after autologous (auto)
eallogeneic (allo) tandem stem cell transplantation (SCT). After induction chemotherapy, patients received
melphalan 200 mg/m2 before undergoing auto-SCT, followed 3 months later by melphalan 140 mg/m2 and
ﬂudarabine 180 mg/m2 before allo-SCT. Sixteen patients had high-risk cytogenetic features, deﬁned by
positive FISH for del(17p13) and/or t(4;14). Overall, 66% of the patients achieved CR or near-CR, and 41%
achieved mCR, which was sustained negative (at least 4 consecutive samples negative) in 15 patients (21%),
with no signiﬁcant difference in incidence between the patients with high-risk cytogenetics and others
(P ¼ .70). After a median follow-up of 6 years, overall 5-year progression-free survival was 29%, with no
signiﬁcant difference between del 17p13/t(4;14)-harboring patients and others (24% versus 30%; P ¼ .70). The
5-year progression-free survival differed substantially according to the achieved remission: 17% for partial
remission, 41% for CR, 57% for mCR, and 85% for sustained mCR. These results suggest that autoeallo tandem
SCT may overcome the negative prognostic effect of del(17p13) and/or t(4;14) and that achievement of
molecular remission resulted in long-term freedom from disease.
 2013 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION [14-17]. In the present study, we investigated within
Multiple myeloma (MM) is considered an incurable
disease, but in some patients long-term survival can be
achieved after high-dose chemotherapy followed by autolo-
gous (auto) or allogeneic (allo) stem cell transplantation
(SCT). Several previous studies have suggested longer
survival in those patients who achieve complete remission
(CR), especially after high-dose chemotherapy [1,2].
Compared with other treatment modalities for MM, allo-SCT
induces a high rate of clinical complete response. Approxi-
mately 50% of patients with CR also achieve CR at the
molecular level (mCR) [3,4]. Only those patients who achieve
mCR have a high probability of long-term freedom from
disease and cure [5].
Standard myeloablative conditioning has been associated
with high treatment-related morbidity and mortality. The
advent of reduced-intensity conditioning (RIC) and the use of
autoeallo tandem SCT approaches has broadened the use of
allo-SCT in patients with MM; however, the results of
prospective trials are controversial [6-13]. Patients harboring
del(17p) or t(4;14) are considered to have worse prognosesalTrials.gov (registration NCT 00781170).
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12.10.008a prospective protocol the incidence and impact of mCR and
of high-risk cytogenetic features, deﬁned as detection of
del(17p13) and t(4;14) by FISH, on long-term outcomes after
autoeallo tandem SCT in patients with MM.
PATIENTS AND METHODS
Patients
Between April 2000 and October 10, 2008, 73 patients with advanced
stage II/III MMwere included in the study. The major inclusion criteria were
MM stage II/III and age 18-65 years. Induction therapy was not part of the
protocol and consisted of idarubicin/dexamethason or vincristine/
adriamycin and dexamethasone and, in more recent years, bortezomib/
dexamethason. Stem cell mobilization was performed with granulocyte
colony-stimulating factor (10 mg/kg) from the steady state. Before auto-
grafting, 3% of the patients were in CR, 59% were in partial remission (PR),
19% had minor response or no change, and 19% had progressive disease. A
minimum dose of 2.0  106/kg CD34þ cells was required for auto-SCT. The
conditioning regimen for auto-SCT consisted of melphalan 200 mg/m2 in
divided doses given over 2 days. After an interval of 2-3months, the patients
received an RIC regimen consisting of melphalan 140 mg/m2, ﬂudarabine
180 mg/m2, and antithymocyte globulin (ATG-Fresenius; Fresenius, Grä-
felﬁng, Germany) at a dose of 10 mg/kg for recipients of related donor grafts
and 20 mg/kg for recipients of unrelated donor grafts on days -3, -2, and -1,
followed by allo-SCT. Twenty-three patients received a graft from an HLA-
identical sibling, and 25 patients each received a graft from a matched or
mismatched unrelated donor.
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine
A and a short course of methotrexate. Additional donor lymphocyte infu-
sions (DLIs) were allowed in cases of incomplete chimerism or persistent
disease by day 120 after discontinuation of immunosuppressive therapy.
FISH analysis was performed in 63 patients and revealed del 13q14 in 43
patients, t4;14 in 8 patients, and del 17q13 in 8 patients. Patienterican Society for Blood and Marrow Transplantation.
Table 1
Patient Characteristics (n ¼ 73)
Characteristic Value
Sex, n
Female 29
Male 44
Donor, n
HLA-identical sibling 23
Unrelated 50
Matched 25
Mismatched 25
Disease status before allo-SCT, n
CR 4
PR 57
mCR 5
Stable disease 3
Progressive disease 4
Del 13q14, n
Positive 43
Negative 20
Unknown 10
t(4;14), n 8
Del 17p13, n 8
Age, years, median (range) 49 (28-64)
Stem cell source, n
Peripheral blood 70
Bone marrow 3
Follow-up, years, median (range) 72 (30-131)
Interval between auto-SCT and allo-SCT, days,
median (range)
110 (39-228)
Remission status after induction therapy, n (%)
CR 2 (3)
PR 43 (59)
mCR 12 (16)
No change 2 (3)
Progressive disease 14 (19)
Table 2
Results
Parameter Value
Primary graft failure, n 1
Time to ANC >1.0  109/L, days, median (range) 15 (11-27)
Time to platelets >20  109/L, days, median (range) 17 (9-122)
Acute GVHD, n (%)
None 31 (43)
Grade I 12 (17)
Grade II 20 (27)
Grade III 9 (12)
Grade IV 1 (1)
Response
CR/near-CR, n (%) 48 (66)
mCR, n 30
Sustained negative 15
Mixed 15
PR, n (%) 15 (21)
Progressive disease, n (%) 2 (3)
Not evaluated, n (%) 8 (11)
5-year PFS, % 29 (17-41)
5-year OS, % 54 (42-66)
Cumulative incidence of relapse at 5 years, % 42 (30-54)
Cumulative incidence of TRM at 1 year, % 23 (13-33)
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years (range, 28-64 years). One patient who experienced severe side effects
from melphalan after auto-SCT received treosulfan (3  10 mg/m2) instead
of melphalan before allo-SCT. The median time from auto-SCT to allo-SCT
was 110 days (range, 39-228 days). Fifteen patients received DLI according
to the protocol due to mixed chimerism or residual disease after discon-
tinuation of immunosuppressive therapy. Preliminary results of this study
have been reported previously [6], and those patients are included in the
present cohort with longer follow-up.
All patients provided informed consent, and the study was approved by
the local Ethics Committee and health authorities. The study has been
registered in ClinicalTrials.gov (NCT 00781170).Response Criteria
The criteria for remission were based on modiﬁed European Group for
Blood and Marrow Transplant (EBMT) criteria [18]. CR was deﬁned as the
absence of detectable monoclonal immunoglobulin in serum and urine,
negative immunoﬁxation, and <5% plasma cells in marrow aspirate. PR was
deﬁned as at least a 75% reduction in monoclonal immunoglobulin in serum
or 90% light chains in 24-hour urine. Near-CR was deﬁned as absence of
visible monoclonal paraprotein in electrophoresis but positive immunoﬁx-
ation in serum or urine. mCR was deﬁned as at least 2 negative PCR results
with ASO primer or at least 2 ﬁndings of 99.9% donor chimerism of CD138-
selected plasma cells by sensitive PCR from bone marrow samples, as
described below.
Sustained minimal residual disease (MRD) negativity was deﬁned by at
least 4 consecutive negativemolecular results by either ASO primer or plasma
cell chimerism. Mixed molecular remission was deﬁned as detection of
negative molecular markers on at least 2 occasions, but with intermittent
positivity as determined by ASO primer or plasma cell chimerism. Positive
MRD was deﬁned as never or only once negativity for ASO primer or plasma
cell chimerism. Bone marrow samples for detection of MRD were obtained
from patients with CR or near CR (deﬁned as normal electrophoresis but
positive immunoﬁxation) in 3- to 6-month intervals during the ﬁrst 3 years
after therapy, usually starting between dayþ100 and dayþ180 after allo-SCT.Molecular Remission Testing
In 37 of 48 patients with CR or near-CR, MRD could be monitored by
patient-speciﬁc primers (n ¼ 15) or by highly sensitive plasma cellchimerism (n ¼ 22). In 5 patients, only 1 MRD measurement was available,
and those patients were excluded from the MRD subanalysis. Myeloma-
speciﬁc primers were generated as described elsewhere [19]. In brief, after
enrichment of CD138þ cells (MACS, Miltenyi, Bergisch Gladbach, Germany),
RNA of plasma cells was isolated and transcripted into cDNA. DNA was
prepared after a preliminary lysis of erythrocytes and centrifugation from
approximately 1-5  105 bone marrow cells using the QIAampDNA DNA
Blood Mini Kit (Qiagen, Hilden, Germany). Four sets of VH consensus
forward primers and one common reverse JH primer were used for IgH
sequence identiﬁcation. Ampliﬁcation products were electrophoresed on 2%
agarose gels with ethidium bromide and visualized. Clonal PCR products
were excised and puriﬁed with a DNA gel extraction kit (Qiagen). Puriﬁed
PCR fragments were sequenced directly using a Big Dye Terminator Kit and
an ABI Prism Model 377 sequencer (Life Technologies, Carlsbad, CA). The
relevant VH family and JH consensus primers were used as sequencing
primers. Vh, Dh, and Jh regions; N nucleotides; and other individual features
of IgH gene were identiﬁed using the IMGT database (http://www.imgt.
cines.fr/) and IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/).
Tumor-speciﬁc primers for nested PCR and as forward and reverse
primers for TaqManwere designed using Primer Express (Life Technologies).
Nested PCR was performed in 2 rounds of ampliﬁcation, with PCR "enrich-
ment" with relevant VH family and JH consensus primers followed by the
second round with a pair of tumor-speciﬁc primers. Parallel analysis of the
HCK gene was performed for ampliﬁcation control.
Determination of plasma cell chimerism was performed as described
previously [20]. In brief, plasma cells were obtained using CD138 microbe-
ads and MiniMACS columns (Miltenyi Biotec), according to the manufac-
turer’s instructions. The genetic markers were selected following Alizadeh
et al. [21], including S01A, S01B, S07A, S07B, S08A, S08B, S11A, and, in cases
of a male recipient and female donor, the DFFRY gene from the Y chromo-
some, as described by Fehse et al. [22]. The reported sensitivity of this
method is 1:1000 cells, 1:100,000 cells for chromosome-speciﬁc PCR.
Quantitative PCR was performed using TaqMan technology on an ABI Prism
7700 sequencer (Life Technologies). Sensitivity of plasma cell chimerism
was assessed by experiments using bone marrow samples from healthy
male donors and dilution experiments using healthy female donor cells.
These experiments revealed a sensitivity of 104 using real-time PCR and
single nucleotide polymorphisms, 105 using Y-chromosome PCR, and 105
using nested PCR with patient-speciﬁc primers.
To determine the relative speciﬁcity threshold of donor plasma cell
chimerism for identifying MRD after allo-SCT, the percentage of donor
plasma cell chimerism was compared with immunoﬁxation and in some
cases with nested PCR of patient-speciﬁc primers. For this study, plasma cell
chimerism was used in those patients in whom generation of speciﬁc
primers was not feasible. In some patients, bothmethods were available and
showed good correlation of results, but patient-speciﬁc primers were used
for the ﬁnal analysis in these patients.
Statistical Methods
Study endpoints were overall survival (OS), progression-free survival
(PFS), transplantation-related mortality (TRM), and incidence of relapse.
Table 3
Results According to CR or mCR
CR versus PR P Value mCR versus Others P Value Sustained mCR versus Mixed mCR P Value
5-year PFS 41% (95% CI, 25-57) versus
17% (95% CI, 0-34) (4 years)
.008 57% (95% CI, 37-77) versus
26% (95% CI, 10-42) (3 years)
<.001 85% (95% CI, 65-100) versus
31% (95% CI, 7-55)
.003
5-year OS 74% (95% CI, 60-88) versus
38% (95% CI, 15-61)
.03 89% (95% CI, 77-100) versus
39% (95% CI, 19-59)
<.001 91% (95% CI, 73-100) versus
87% (95% CI, 69-100)
.06
5-year relapse 45% (95% CI, 29-61) versus
56% (95% CI, 31-81) (4 years)
.44 36% (95% CI, 18-54) versus
55% (95% CI, 34-76)
.06 7% (95% CI, 0-21) versus
63% (95% CI, 35-91)
.002
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variables and as frequency for categorical variables. Categorical data were
compared using the c2 test or the Fisher exact test. Survival curves were
estimated by the Kaplan-Meier method. The log-rank test was used to
estimate the incidence of TRM and relapse, to account for competing risks.
For TRM, relapse was the competing event and for relapse, TRM was the
competing event. Gray’s test was used to compare cumulative incidence
curves. Calculations were performed with SPSS version 15 (SPSS, Inc., Chi-
cago, IL), and the competing-risk analyses were done using ACCorD (V.
Gebski, National Health and Medical Research Council Clinical Trials Centre,
Camperdown, Australia).
RESULTS
Engraftment
One graft failure was observed. The median time to
leukocyte and platelet engraftment was 15 days (range,11-27
days) and 17 days (range, 9-122 days), respectively (Table 2).
TRM
The cumulative incidence of 1-year TRMwas 23% (95% CI,
13%-33%). This incidence was identical in HLA-identicalInclude
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Response
A total of 44 patients (60%) achieved CR according to
EBMT criteria with negative immunoﬁxation, 6% achieved
near-CR, and 21% achieved PR. In addition, 3% had progres-
sive disease, and 11%were not evaluable for determination of
remission. mCR was observed in 30 patients; in 15 of these
patients, the molecular markers were sustained negative,
and in the other 15 patients, the molecular markers were
only mixed negative as described above, resulting in an
overall mCR rate of 41% and a sustained mCR rate of 21%. The
mCR rate was 50% in patients with del 17p/t(4;14) and 40% in
those without del 17p/t(4;14) (P ¼ .50). Sustained mCR was
seen in 6 patients with del 17p and/or t(4;14) and in 9
patients without del 17p/t(4;14) (P ¼ .70) (Table 3).d patients 
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disease after discontinuation of immunosuppressive therapy.
A total of 15 patients received DLI, 8 of whom achieved mCR
(mixed in 3 and sustained in 5). In 3 of these responding
patients, mCRwas associatedwith the development of GVHD
(Table 3 and Figure 1). Figure 2 shows the occurrence of mCR,
along with the dates of DLI and relapse.
PFS
At a median follow-up of 6 years, overall 5-year PFS was
29% (95% CI, 17%-41%). PFS at 5 years did not differ between
patients with del 17p/t(4;14) and those without del 17p/
t(4;14) (24% versus 30%; P ¼ .70). Patients who achieved CR
after transplantation had a better 5-year PFS compared with
patients with only PR (41% versus 17%; P ¼ .008). Within
the group that achieved CR according to EBMTcriteria, 3-year
PFS was signiﬁcantly better in the patients who achieved
mCR compared with those who did not (57% versus 26%: P 
.001). However, in the group of patients who achieved mCR,
those with sustained negative mCR had a 5-year PFS of 85%,
versus 31% for those with mixed mCR (P ¼ .003) (Table 3).The 5-year OS for the entire study population was 54%
(95% CI, 42%-66%). Donor source, HLA mismatch, or remis-
sion before transplantation did not inﬂuence OS. Patients
who achieved CR according to EBMT criteria had an
improved 5-year OS comparedwith thosewho achieved only
PR (74% versus 38%; P ¼ .03). Patients who achieved mCR
had a better 5-year OS than those who did not (89% versus
39%; P < .001). There was also a trend toward improved OS
in patients with sustained mCR versus those with mixed
mCR (91% versus 87%; P ¼ .06). The 5-year OS did not differ
among recipients of grafts from HLA-identical siblings,
matched donors, or mismatched donors (65% versus 40%
versus 51%, respectively; P ¼ .30) (Figure 3A and B).
Relapse
The cumulative incidence of relapse at 5 years was 42%
(95% CI, 30%-54%) and was not inﬂuenced by the presence of
del 17p or t(4;14) (40% versus 52%; P ¼ .10). Patients with
mCR exhibited a trend toward a lower incidence of relapse
(36% versus 55%; P ¼ .06). Patients with sustained mCR had
a relapse incidence of only 7% (95% CI, 0-21%) at 5 years,
Figure 3. OS (A) and PFS (B) after autoeallo tandem SCT according to
achievement of mCR.
Figure 4. Cumulative incidence of relapse after autoeallo tandem SCT
according to achievement of mCR.
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(Figures 1 and 4).DISCUSSION
The achievement of CR is now considered a major factor
for prolonged event-free survival and OS in patients with
MM who receive standard chemotherapy or high-dose
chemotherapy followed by auto-SCT or allo-SCT [23].
Furthermore, duration of CR in the sense of sustained CR is
a major factor for long-term survival after auto-SCT [24].
mCR is rarely observed after auto-SCT [3,4], but can be ach-
ieved in some patients by posttransplantation consolidation
or maintenance therapy [25]. After standard myeloablative
conditioning followed by allo-SCT, approximately 50% of the
patients who achieve CR will also achieve mCR [3,4], but this
treatment approach is associated with high treatment-
related morbidity and TRM [26,27]. The introduction of RIC
has broadened the application of allografting in MM, owing
to the reduced treatment-related morbidity and TRM. Some
randomized studies using an autoeallo tandem SCT
approach have suggested a beneﬁt for OS [9-13,28].
The incidence and outcome of mCR after RIC have not
been previously studied in a large cohort of patients [29].
Here we report that 66% of patients achieved CR and 41%
achieved mCR according to EBMT criteria with RIC autoeallo
tandem SCT. Sustained mCR, deﬁned as 4 consecutive MRD-
negative bone marrow samples, was achieved in 21% ofpatients. Those with sustainedmCR had a signiﬁcantly better
5-year PFS than those who achieved only mixed mCR or no
mCR (85% versus 31% versus 17%, respectively), supporting
previously published results on mCR after standard mye-
loablative conditioning [5]. Our 21% rate of sustained mCR
after RIC is somewhat lower than the reported 50% after
myeloablative conditioning [3,4], possibly related to meth-
odological differences and the stringent deﬁnition of “sus-
tained”mCR in our study. Of note, PFS increased according to
the depth of remission, from 41% for CR to 57% in mCR and
85% in sustained mCR. Furthermore, only those patients with
sustained mCR, deﬁned as 4 consecutive negative samples,
are at very low risk of relapse at 5 years (7%), whereas those
with mixed mCR have only a delayed onset of relapse, but
identical cumulative incidence at 5 years (Figure 2).
The International Myeloma Working Group recently
introduced a stringent deﬁnition of CR [30], but comparative
studies have shown no further beneﬁt from adding the free
light chain ratio to the standard EBMT deﬁnition of CR
[31,32]. The most sensitive methods are molecular methods,
especially the use allelic-speciﬁc primers based on IgH
rearrangement, with a sensitivity up to 106 [3,4,5,25].
Shortcomings of this approach include the time-consuming
procedure, generation of individual patient-speciﬁc
primers, and a success rate of <75%. Owing to pretreat-
ment with induction chemotherapy, we were able to
generate patient-speciﬁc primers in only 45% of our patients.
To overcome this limitation, we used a highly sensitive
plasma cell chimerism with a sensitivity of 105, which has
the advantage of being less time-consuming [20]. Among the
disadvantages of this approach are the low speciﬁcity and its
applicability only after allo-SCT. Whereas complete donor
plasma cell chimerism is closely correlated with speciﬁcity of
patient-speciﬁc primers, in cases of mixed plasma cell
chimerism, this method does not allow differentiation
between residual healthy and malignant plasma cells. Other
investigators have used multicolor ﬂow cytometry to detect
MRD, which is readily applicable but has a lower sensitivity,
w104, compared with molecular methods [32,33].
No clear characteristics were identiﬁed in those patients
who achieved sustained mCR. Interestingly, long-lasting
mCR was seen in patients harboring del 17p13 or t(4;14)
Table 4
Characteristics of Patients Who Achieved Sustained mCR
Type Sex Donor Cytogenetics (by FISH) Status after
Induction
Status before
Allo-SCT
GVHD after SCT DLI for
MRD
Status at Follow-up
IgG kappa Male MUD del 13q14, t(4;14) CR CR Ø Yes Relapse after 7 years; alive
9 yearsþ
Light chain/plasma
cell leukemia
Female MUD del 13q14, t(14;16) PR PD Ø No Alive, mCR, 8 yearsþ
IgA kappa Male MUD del 13q14; del 17p13,
t(4;14)
PR PR Chronic GVHD No Dead, chronic GVHD, 5 years
in mCR
IgA lambda Female MUD t(4;14), del 13q14 PR PR Ø Yes Alive, mCR, 7 yearsþ
IgG kappa Male MUD del 13q14 PR PR Ø No Alive, mCR, 6.5 yearsþ
IgA lambda þ
extramedullary
Male Related Not done PR PR Ø No Alive, mCR, 6.5 yearsþ
Light chain kappa Male MUD Normal PR PR Chronic GVHD No Alive, mCR 6 yearsþ
IgA lambda Female Related del17p13/ del 13q14 PR CR ChronicGVHD No Relapse after 3.5 years; alive
4.5 yearsþ
IgG lambda þ
extramedullary
Male MUD Not done PR PR Ø Yes Alive, mCR, 9.5 yearsþ
IgG kappa Female MUD del 13q14 PR PR Ø No Alive, mCR, 4.5 yearsþ
IgG kappa Male Related Unknown PR PR Ø No Alive, mCR, 11.5 yearsþ
IgG kappa Male Related Normal PR PR Ø Yes Alive, mCR, 10.5 yearsþ
IgG kappa Male MUD Not done PR PR Chronic GVHD Yes Alive, mCR, 11yearsþ
IgG kappa Male Related del17p13 PR PR Acute GVHD
grade II
No Alive, mCR, 4.5 yearsþ
Light chain kappa Male MUD del 13q14, del 17p13 PD PR Ø No Alive, mCR, 4.5 yearsþ
MUD indicates matched unrelated donor; PD, progressive disease.
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plantation (Table 4).
Patients with del 17p and/or t(4;14) and those without
these high-risk cytogenetic features had similar rates of mCR
and relapse, as well as similar PFS, suggesting that these
negative prognostic factors may be overcome by an upfront
autoeallo tandem SCT approach. Previous studies in patients
with more advanced disease have shown a negative impact
of del 17p, but not of t(4;14), after allo-SCT [34,35]. More
recently, the Société Française de Greffe de Moelle et de
Thérapie Cellulaire reported no difference in outcomes
between patients with or without del 17p and/or t(4;14) after
allo-SCT [36]. Interestingly, no difference in outcomes was
seen between recipients of HLA-identical sibling grafts and
recipients of unrelated donor grafts, which is important
because unrelated SCT as part of an autoeallo tandem
approach has been reported only rarely [37].
Of note, 5 of 15 patients who received DLI because of
persistent disease achieved sustained mCR. This ﬁnding
supports strategies to target mCR by posttransplantation
therapies for those who did not achieve mCR from the
transplantation itself. To improve results, post-
transplantation strategies including, for instance, DLI or
novel immunomodulating drugs, such as thalidomide, lena-
lidomide, and bortezomib, can be used to upgrade CR to
mCR, as reported recently [38,39]. The present study
underscores the importance of the depth of remission and
demonstrates that achievement of mCR is associated with
long-term freedom from disease and potential cure of MM
and, even more important, that this can be achieved in
patients with high-risk cytogenetics, deﬁned by del 17p and/
or t(4;14).
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